AstraZeneca’s Reported $10 Billion Rhythm Bid Targets Rare Obesity
AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals, Reuters reports. Rhythm’s latest results show the attraction of its rare-obesity franchise, but milestone payments complicate the headline price.

Follow